# VERTEX PHARMACEUTICA (VRTX) — Q3-2017 Earnings Results

**Report date:** 2017-10-25 (after market close)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/VRTX/earnings/Q3-2017

## Post-Earnings Brief

### Headline

Vertex Pharmaceuticals Beats on EPS, Stock Down 2.85%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.53 | N/A | +41.71% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Management expressed satisfaction with the EPS results, highlighting strong operational performance. However, they did not offer any guidance for future earnings.

**Key quotes:**

> The company is pleased with the EPS performance this quarter.

> Management did not provide specific guidance for future quarters.

### Guidance Changes

No guidance updates were provided during the earnings call.

### What It Means

Vertex Pharmaceuticals reported a strong EPS that beat expectations, indicating solid financial performance. However, the stock fell by 2.85% following the earnings report, likely due to the lack of revenue details and future guidance. Investors may be cautious as they await more information on the company's outlook.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/VRTX/earnings/Q3-2017_